Opinion: To make advanced therapies, we need to industrialize personalization
Advanced therapies are beginning to transform the lives of thousands of patients. We need to make that possible for many, many more by industrializing and personalizing in parallel.
What’s the best way to measure the real rate of progress in personalized cell therapies, gene therapies, and other advanced therapies?
I’ve been tracking the ever-growing flow of reports about these therapies in scientific journals and press releases for 15 years, ever since I co-led the passage of California’s $3 billion Stem Cell Research and Cures Act in 2004.
But to truly gauge who will benefit from today’s innovations, I’ve learned I also need to study the stream of business and technology announcements that runs in parallel. That might seem more mundane — but to
